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The effects of enzalutamide monotherapy on prostate tumor downsizing and multiparametric MRI are
currently unknown. Here we present the ﬁrst case in literature of a patient with high-grade prostate cancer
who underwent 3 months of neoadjuvant enzalutamide, for which the effects on mpMRI and histology
were determined. Tumor size reduction and downstaging were noted. Neoadjuvant enzalutamide resulted
in an increase in ADC value on the DWI-MRI sequences. Histological changes were also observed.
 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Androgen ablation is the cornerstone of systemic prostate cancer
treatment. This can either be achieved by (chemical) castration
with GnRH/LH-RH-analogues alone or in combination with
androgen receptor inhibitors. Over time, multiple androgen re-
ceptor inhibitors have been developed, with increasing efﬁcacies
in blocking androgen action. Initially, ﬂutamide was developed as
a non-steroidal antiandrogen. Subsequently, other non-steroidal
antiandrogens such as nilutamide and bicalutamide were intro-
duced, with longer half-lives and reduced toxicity.1 Second gen-
eration antiandrogens such as enzalutamide (Xtandi, Astellas
Pharma; Medivation) showed increased androgen receptor
blockade, inhibition of receptor nuclear translocation andþ31 20 5122459.
est).
Inc. This is an open access articlediminished DNA-binding2 that resulted in a survival beneﬁt in
men with castration resistant cancer.3,4 The effects of enzaluta-
mide monotherapy on cell growth have not extensively been
studied in hormone-naïve prostate cancer patients.
Neoadjuvant androgen ablation prior to prostatectomy has
shown to result in tumor downstaging, reduction in surgical positive
margin-rates, decreased lymph node invasion and reduced blood
loss.5e7 Although generally found not to affect overall survival,6 in
men with PSA > 20 ng/mL neoadjuvant cyproterone acetate treat-
ment was found to improve recurrence-free survival.4 Therefore, we
started a phase II window study on the efﬁcacy of enzalutamide in
hormone-naïve patients in the preoperative setting; tissue is
analyzed before and after 3 months of neoadjuvant 160 mg daily
enzalutamidemonotherapy (NL47463.031.14). In this study, potential
tumor downstaging is assessed in men who undergo prostatectomy
for intermediate or high-risk prostate cancer.
Multiparametric (mp) MRI is presently used to grade and stage
men with prostate cancer preoperatively. Androgen ablation wasunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Functional imaging data before and after enzalutamide monotherapy.
Before enzalutamide
monotherapy
After 3 months of enzalutamide
monotherapy
ADC* (103 mm/s)
Tumor 0.75  0.13 1.28  0.17
Healthy PZ0 1.83  0.19 2.05  0.32
Ktrans’ (min1)
Tumor 0.44  0.08 0.13  0.02
Healthy PZ 0.13  0.02 0.08  0.02
Data presented as mean  standard deviation.
* ¼ apparent diffusion coefﬁcient; ’(PZ) ¼ peripheral zone; ’ ¼ volume transfer
constant.
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enzalutamide monotherapy on tumor downsizing and mpMRI are
currently unknown. Here, we present the case of a patient with
high-grade prostate cancer who underwent 3 months of neo-
adjuvant enzalutamide, and for whom treatment effects on mpMRI
and histology were assessed.
Case report
A 62-year-old man was diagnosed with prostate cancer at a PSA
of 8.5 ng/mL and Gleason score 4 þ 4 ¼ 8 in 4 of 6 biopsies on the
left and Gleason score 3 þ 3 ¼ 6 in 3 of 6 biopsies on the right in a
36 cc prostate. Digital rectal examination revealed suspicion for a
cT2b tumor in the right lobe. Transrectal ultrasound showed a
tumor in the peripheral zone on the left side staged as cT2b. The
patient participated in the above mentioned clinical study
approved by the local ethical committee.
Pretreatment
Multiparametric 3T MRI was performed prior to enzalutamide
treatment using a pelvic coil in combinationwith an endorectal coil
(Achieva, Philips, the Netherlands) and included T2-weighted
imaging, diffusion weighted imaging (DWI) and dynamic
contract-enhanced imaging (DCE-MRI). The apparent diffusion
coefﬁcient (ADC) was calculated from DWI-images using b-values
200, 600, and 1000 s/mm2. Pharmacokinetic analysis with the Tofts
model was performed of DCE-images (temporal resolution 2.7 s)
resulting in Ktrans maps (volume transfer constant from blood
plasma to extravascular extracellular space). Imaging suggested
extraprostatic extension (mcT3aN0Mx) in the left lobe with an
ADC value of 0.75  103 mm2/s suspicious for high-grade
prostate cancer. The tumor on the right was difﬁcult to differ-
entiate on MRI.
After treatment
After enzalutamide pretreatment PSA dropped to 1.2 ng/mL. The
second mpMRI showed prostate size reduction of 27% and tumor
size reduction of 83%. Interestingly, alterations weremost markedly
present in functional imaging data (Fig. 1): mean ADC increasedFigure 1. MpMR images and histology before and after 3 months of enzalutamide monother
contrast uptake curve in tumor area, and corresponding histology of the left prostate lobe.from 0.75  103 mm2/s in the pretreatment mpMRI compared to
1.28  103 mm2/s in the mpMRI after enzalutamide (Table 1). The
ADC in a ROI (region of interest) in healthy peripheral zone did not
change signiﬁcantly. In DCE-MRI, a clear reduction in tumor
perfusion and gadoliniumwashout was visible: Ktrans reduced from
0.44 min1 pretreatment to 0.13 min1 after enzalutamide. A small
reduction in perfusion was visible in healthy peripheral zone (from
0.13 to 0.08 min1).
For histologic evaluation, prostate base and apex were lami-
nated parasagittally after formalin ﬁxation overnight. Remaining
prostate parts were laminated transversely in whole mount 4 mm
slices. Hematoxylin and eosin stained slides were evaluated by a
urogenital pathologist (JdJ). The neoadjuvant treatment effect was
heterogeneous, with only focal areas of tumor cells with severe
treatment effect consisting of cells with pyknotic nuclei and
abundant xanthomatous cytoplasm (Fig. 1). Residual tumor was
scattered multifocal with dominant lesions at the apex on the left
and in central slides ventral on the right. TNM (7th edition) stage
was ypT2cN0Mx. Because of treatment effect, no Gleason score was
assigned.Discussion
Androgen ablation was earlier found to be of limited value in a
neoadjuvant setting prior to prostatectomy.5e7, 9 Although positive
margin-rates were found decreased in men with neoadjuvantapy. Subsequently, transversal T2-weighted image, ADC map from DWI, Ktrans map with
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antiandrogen treatment options were found to improve survival in
menwith metastasized disease3 and are effective in a monotherapy
setting,4 it may be of value to re-explore their role in localized
disease.
We present the ﬁrst case in literature depicting the effects of
neoadjuvant enzalutamide in high-risk prostate cancer using
mpMRI and histological evaluation. Surprisingly, little is known on
histopathological characteristics that are causative of altered
mpMRI-ﬁndings so well studied in the detection of prostate cancer.
The neoadjuvant setting provides an interesting opportunity to
correlate histology with mpMRI-ﬁndings in relation to androgen
ablation. Earlier studies after chemotherapy indicated that marked
MRI changes were associated with partial tumor responses in 27%,
although MRI response was not clearly predictive of postoperative
recurrence-free survival.10 Alterations on mpMRI after enzaluta-
mide monotherapy and correlation with histology have not been
thoroughly studied. In the presented case a tumor size reduction of
83% was noted after enzalutamide use. This downsizing was asso-
ciated with downstaging on MRI from T3a to T2c. Interestingly,
neoadjuvant enzalutamide also resulted in an ADC value increase
on DWI-MRI sequences suggestive of reduction in cell density.
Histological changes were also observed. Both tumor downsizing
and downstaging was achieved in this case by means of neo-
adjuvant enzalutamide.
This case shows, for the ﬁrst time, the effects of enzalutamide
monotherapy on primary prostate cancer usingMRI. The alterations
onmpMRI parameters were remarkablymore pronounced in tumor
compared to normal prostate tissue.Conﬂicts of interest
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